ar101 - search results

If you're not happy with the results, please do another search
AR101+dupilumab

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to Begin

Study scheduled to commence next week.
Paliforzia (AR101)

Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate

The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Palforzia

New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients...

After 2 Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels.
Aimmune + Xencor

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food...

“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
Palforzia

FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy

Palforzia is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
AAAAI Logo + Palforzia

AAAAI Addresses What Patients and Their Families Need to Know About Oral Immunotherapy (OIT)

As the FDA moves closer to approving the first food allergy treatment, the AAAAI seeks to help patients and their families understand the realities surrounding OIT.
Paliforzia (AR101)

FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy

What it is, what it treats, who it is for, how it is used, et al.
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
AAFA Reponse to ICER Report

Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut...

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
ICER Final Report

ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...

The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).